(S1 (S (S (NP (JJ Hypoxia-responsive) (JJ element-mediated) (JJ soluble) (NN Tie2) (NN vector)) (VP (VBZ exhibits) (NP (DT an) (JJ anti-angiogenic) (NN activity)) (ADVP (FW in) (FW vitro)) (PP (IN under) (NP (JJ hypoxic) (NN condition))))) (. .)))
(S1 (S (S (NP (NP (JJ Hypoxia-inducible) (NN factor-1)) (PRN (-LRB- -LRB-) (NP (NN HIF-1)) (-RRB- -RRB-))) (VP (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ key) (JJ mammalian) (NN transcription) (NNS factors))))) (CC and) (VP (VBZ shows) (NP (NP (VBN increased) (NNS levels)) (PP (IN in) (NP (NP (CC both) (NP (NN protein) (NN stability)) (CC and) (NP (JJ intrinsic) (JJ transcriptional) (NN activity))) (PP (IN during) (NP (JJ low) (NN oxygen) (NN tension))))))))) (. .)))
(S1 (S (S (NP (JJ Hypoxia-activated) (JJ functional) (NN HIF-1) (NN protein)) (VP (VP (VBZ binds) (PP (TO to) (NP (NP (NP (JJ hypoxia-responsive) (NNS elements)) (PRN (-LRB- -LRB-) (NP (NN HRE)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (NNS enhancers)) (PP (IN of) (NP (NP (JJ several) (NNS genes)) (PP (VBG including) (NP (NP (NN VEGF)) (, ,) (NP (NP (DT the) (JJ major) (NN player)) (PP (IN in) (NP (NN angiogenesis)))) (, ,)))))))))) (CC and) (VP (VBZ initiates) (NP (PRP$ their) (NN mRNA) (NN expression))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ molecular) (NNS mechanisms)) (VP (VBG regulating) (NP (DT the) (NN gene) (NN expression)) (PP (IN under) (NP (JJ hypoxic) (NNS conditions))))) (VP (MD could) (VP (VB increase) (NP (NP (DT the) (JJ therapeutic) (NN window)) (PP (IN of) (NP (JJ tumor-specific) (NN delivery) (NNS systems))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (S (S (VP (TO to) (VP (VB examine) (NP (NP (JJ hypoxia-specific) (NN production)) (PP (IN of) (NP (JJ anti-angiogenic) (JJ therapeutic) (NN gene))))))) (, ,) (S (NP (PRP we)) (VP (VBD constructed) (NP (NP (CD 5) (NNS copies)) (PP (IN of) (NP (NP (NP (NN HRE)) (PRN (-LRB- -LRB-) (NP (NN 5xHRE)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ human) (NN VEGF)) (VP (VBN linked) (PP (TO to) (NP (NP (NP (JJ soluble) (NN Tie2)) (PRN (-LRB- -LRB-) (NP (NN sTie2)) (-RRB- -RRB-))) (VP (VBN driven) (PP (IN by) (NP (NP (JJ minimal) (NN SV40) (NN promoter)) (PRN (-LRB- -LRB-) (NP (NN 5xHRE/SV40/sTie2)) (-RRB- -RRB-)))))))))))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBD showed) (SBAR (IN that) (S (PP (IN under) (NP (NN hypoxia))) (NP (DT the) (VBN secreted) (NN sTie2)) (ADVP (RB selectively)) (VP (VBD inhibited) (NP (NP (NP (NN tube) (NN formation)) (CC and) (NP (NN migration) (NNS capacities))) (PP (IN of) (NP (JJ endothelial) (NNS cells)))) (ADVP (FW in) (FW vitro))))))) (. .)))
(S1 (S (S (ADVP (RB Hence)) (, ,) (NP (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP (NP (DT the) (NN vector) (NN system)) (, ,) (NP (NN 5xHRE/SV40/sTie2)) (, ,)) (VP (MD might) (VP (VB be) (NP (NP (DT a) (JJ useful) (NN tool)) (PP (IN for) (S (VP (VBG down-regulating) (NP (NN tumor) (NN angiogenesis)) (PP (IN under) (NP (JJ hypoxic) (NN condition))))))))))))) (. .)))
